Compare Crispr Therapeutics AG (CRSP) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Devon Energy Corp — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Devon Energy Corp trades at $44.87 (market cap $49.94B). The key difference: Devon Energy Corp is far larger — about 9.5× Crispr Therapeutics AG's market cap, and Devon Energy Corp pays a 2.82% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | DVN | |
|---|---|---|
Market Cap | $5.23B | $49.94B |
Sector | Health | Energy |
52-Week High | $76.78 | $52.07 |
52-Week Low | $44.34 | $31.74 |
Enterprise Value | $3.65B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Devon Energy (DVN) trades at $44.9, down 1.01% today, with a bullish technical signal and strong Q2 2026 earnings beat. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil prices. Valuation remains attractive with a P/E of 9.87 and P/S of 1.62. Recent news highlights a 33% dividend increase and $1.25 billion debt repayment, reinforcing financial health.
The outlook is positive given robust free cash flow, debt reduction targets, and analyst consensus price target of $61.91 implying 38% upside. Key risks include oil price volatility and integration challenges from the Coterra merger. Institutional sentiment is strongly bullish with 71% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
